• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

225.00 +28.00 (+14.21%)
Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell? ↗
October 10, 2026
After a few years of stagnation, this stock is soaring. 
Via The Motley Fool
News headline image
Why Moderna Stock Surged Today ↗
October 09, 2026
The biotech could play a significant role in a national effort to combat cancer. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
This Stock Is Up More than 560% This Year, but It Could Drop by 38%, According to Wall Street ↗
October 09, 2026
Have Moderna’s shares risen too much, too fast? 
Via The Motley Fool
These S&P500 stocks are moving in today's pre-market session ↗
September 30, 2026
Via Chartmill
Explore the S&P500 index on Friday and find out which stocks are the most active in today's session. ↗
October 09, 2026
Via Chartmill
Discover which S&P500 stocks are making waves on Friday. ↗
October 09, 2026
Via Chartmill
News headline image
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? ↗
October 07, 2026
Axsome is posting 65% revenue growth but burning cash, while Moderna's vaccine market is cooling yet its oncology pipeline carries transformative potential. 
Via The Motley Fool
Exploring the top movers within the S&P500 index during today's session. ↗
October 07, 2026
Via Chartmill
News headline image
Is Now the Time to Cash Out of the S&P 500's Top 3 Stocks of 2026? ↗
October 06, 2026
These stocks have all soared more than 350% this year. 
Via The Motley Fool
Topics Artificial Intelligence Stocks
Uncover the latest developments among S&P500 stocks in today's session. ↗
October 06, 2026
Via Chartmill
Which S&P500 stocks are moving on Tuesday? ↗
October 06, 2026
Via Chartmill
Tuesday's session: gap up and gap down stock in the S&P500 index ↗
October 06, 2026
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session. ↗
October 05, 2026
Via Chartmill
A Soft Jobs Report Takes the Heat Off Rates, and Nvidia Closes In on $6 Trillion ↗
October 05, 2026
Via Chartmill
News headline image
1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Headwinds
October 05, 2026
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Lu... 
Via StockStory
Topics Economy
News headline image
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet
October 01, 2026
Check out the companies making headlines yesterday: United Therapeutics (NASDAQ:UTHR): Biotechnology company United Therapeutics (NASDAQ:UTHR) rose by 13.6% ... 
Via StockStory
Topics Intellectual Property
News headline image
If I Could Tell Every New Investor 1 Thing About Building Wealth in the Stock Market, It's This ↗
October 01, 2026
New investors might be eager to jump in during a bull market. 
Via The Motley Fool
Top S&P500 movers in Wednesday's session ↗
September 30, 2026
Via Chartmill
News headline image
Prediction: Moderna Stock Will Soar 100% by 2030 ↗
September 30, 2026
The company could enter a fresh growth phase. 
Via The Motley Fool
Uncover the latest developments among S&P500 stocks in today's session. ↗
September 30, 2026
Via Chartmill
News headline image
Why Moderna (MRNA) Shares Are Falling Today
September 30, 2026
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6% in the morning session after Citigroup downgraded the company to Sell from Neutr... 
Via StockStory
Wednesday's session: gap up and gap down stock in the S&P500 index ↗
September 30, 2026
Via Chartmill
News headline image
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
September 30, 2026
Juan Andres to Return to Moderna as Chief Operating Officer Jerh Collins to Retire Following Four Years of Leadership at Moderna 
From Moderna, Inc.
Via ACCESS Newswire
News headline image
2 S&P 500 Stocks to Consider Right Now and 1 We Question
September 29, 2026
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec... 
Via StockStory
Topics Stocks
News headline image
Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside? ↗
September 28, 2026
Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase. 
Via The Motley Fool
News headline image
Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock? ↗
September 28, 2026
Positive news surrounding its personalized cancer vaccine has lit a fire under the healthcare stock. 
Via The Motley Fool
These S&P500 stocks that are showing activity before the opening bell on Monday. ↗
September 28, 2026
Via Chartmill
Discover which S&P500 stocks are making waves on Thursday. ↗
September 24, 2026
Via Chartmill
News headline image
Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID ↗
September 23, 2026
Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program... 
Via MarketBeat
News headline image
Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success? ↗
September 22, 2026
The company is looking to prove it can achieve significant success outside the coronavirus market. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap